Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
547 stopped studies mapped to Malignant Nervous System Neoplasm and descendants · 90% state a reason
Over the 547 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01868906 | FMISO-PET in Brain Tumors and SCS Effect(FMISOPETSCS) | Phase 2 | terminated | Jun 5, 2013 | Bernardino Clavo, MD, PhD | Isotope (FMISO) production is no longer available in our country. | Other (stated, no rule matched) |
| NCT02337309 | SF1126 for Patients With Relapsed or Refractory Neuroblastoma | Phase 1 | terminated | Jan 13, 2015 | New Approaches to Neuroblastoma Therapy Consortium | Low patient accrual | Enrollment / accrual |
| NCT02062372 | Spatial Analysis and Validation of Glioblastoma on 7 T MRI | N/A | terminated | Feb 13, 2014 | Maastricht Radiation Oncology | Expectation that within the set time period insufficient patients will be included, so endpoints… | Other (stated, no rule matched) |
| NCT02176720 | Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma | Phase 1 | terminated | Jun 27, 2014 | The Methodist Hospital Research Institute | PI left HMRI | Investigator |
| NCT01453465 | Biomarker Study in Samples From Patients With Malignant Rhabdoid Tumor of the Kidney or… | — | withdrawn | Oct 17, 2011 | Children's Oncology Group | not stated | Not stated |
| NCT02011126 | Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors | Phase 2 | withdrawn | Dec 13, 2013 | Children's Oncology Group | IND no longer available. | Other (stated, no rule matched) |
| NCT01103375 | Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant… | Phase 1 | terminated | Apr 14, 2010 | Wake Forest University Health Sciences | Slow accrual | Enrollment / accrual |
| NCT01575275 | Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma… | Phase 2 | terminated | Apr 11, 2012 | Michael Vogelbaum, MD, PhD | Drugs unavailable | Other (stated, no rule matched) |
| NCT01836549 | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | Phase 2 | terminated | Apr 22, 2013 | Pediatric Brain Tumor Consortium | Due to several intracranial hemorrhages and recommendation by the PBTC DSMB. | Other (stated, no rule matched) |
| NCT02540135 | Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma | N/A | withdrawn | Sep 3, 2015 | University of Colorado, Denver | The investigators decided not to move forward with this study at this time. | Other (stated, no rule matched) |
| NCT03275558 | Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma | Phase 1 | withdrawn | Sep 7, 2017 | Center Trials & Treatment | Study halted prior to enrollment of first participant. (It has been determined on 2018 May 15 that… | Enrollment / accrual |
| NCT01281982 | (11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas | — | terminated | Jan 24, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01086345 | Radiosurgery Plus Bevacizumab in Glioblastoma | Early Phase 1 | terminated | Mar 15, 2010 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT01234805 | Yoga Therapy in Treating Patients With Malignant Brain Tumors | N/A | terminated | Nov 4, 2010 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
| NCT02375334 | Adherence Monitoring System in Managing Myelosuppression in Patients With Newly Diagnosed… | — | terminated | Mar 2, 2015 | Wake Forest University Health Sciences | Support Staff Left Institution | Other (stated, no rule matched) |
| NCT01987193 | Feasibility Study of Tumor Blood Flow Measurement by Detection of Positron Activation… | — | terminated | Nov 19, 2013 | University of Florida | Slow accrual; funding stopped | Enrollment / accrual |
| NCT02332889 | Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade… | Phase 1 / Phase 2 | terminated | Jan 7, 2015 | University of Louisville | Transition to a different immunotherapy strategy in the future at our institution | Sponsor / business decision |
| NCT00990496 | A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme… | Phase 1 | terminated | Oct 6, 2009 | Milton S. Hershey Medical Center | Accrual goals not met | Enrollment / accrual |
| NCT02227576 | Prevention of Thrombocytopenia in Glioblastoma Patients(PLATUM) | Phase 2 | terminated | Aug 28, 2014 | University Hospital, Lille | Study halted for efficacy following the results of the interim analysis provided for in the… | Efficacy / futility |
| NCT01702792 | Derivation of Tumor Specific Hybridomas | Phase 1 | terminated | Oct 8, 2012 | Dartmouth-Hitchcock Medical Center | Investigator is leaving Dartmouth | Investigator |
| NCT02365662 | A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced… | Phase 1 | terminated | Feb 19, 2015 | AbbVie | Safety | Safety / toxicity |
| NCT02654041 | Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients | Phase 2 | terminated | Jan 13, 2016 | Musli Thyropeutics Ltd. | Drug manufacturer no longer could supply for study | Drug supply |
| NCT02254954 | Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance… | Phase 1 | terminated | Oct 2, 2014 | Actelion | Sponsor decision due to low recruitment | Enrollment / accrual |
| NCT02617862 | PCI Imaging System in Pediatric Ophthalmology | N/A | terminated | Dec 1, 2015 | Brenda Gallie | Proposed comparison (RetCam vs. COSMOS) was unfeasible. Device is now licensed in Canada. | Other (stated, no rule matched) |
| NCT01788280 | Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma… | Phase 2 | withdrawn | Feb 11, 2013 | University of Utah | Unable to get materials from GE, study not proceeding and never opened to accrual | Enrollment / accrual |
| NCT02047214 | Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed… | Phase 2 | terminated | Jan 28, 2014 | Cortice Biosciences, Inc. | Due to lack of clinical benefit in the 17 subjects enrolled in the trial to date | Efficacy / futility |
| NCT02590497 | Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed… | N/A | withdrawn | Oct 29, 2015 | Ohio State University Comprehensive Cancer Center | PI made decision | Other (stated, no rule matched) |
| NCT01740570 | Phase I/II Cabazitaxel for Recurrent Malignant Glioma | Phase 1 / Phase 2 | withdrawn | Dec 4, 2012 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT01782976 | Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM) | Phase 2 | withdrawn | Feb 4, 2013 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT01418001 | Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the… | Phase 1 / Phase 2 | terminated | Aug 16, 2011 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT02348255 | NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma… | Phase 2 | withdrawn | Jan 28, 2015 | University of California, Davis | Poor Accrual | Enrollment / accrual |
| NCT00602446 | Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell… | Phase 2 | terminated | Jan 28, 2008 | Masonic Cancer Center, University of Minnesota | Due to slow accrual of patients | Enrollment / accrual |
| NCT02164097 | ODSH + ICE Chemotherapy in Pediatric Solid Tumors | Phase 1 | terminated | Jun 16, 2014 | New York Medical College | low accrual | Enrollment / accrual |
| NCT00623077 | MT2004-30: Tomotherapy for Solid Tumors | Phase 1 | terminated | Feb 25, 2008 | Masonic Cancer Center, University of Minnesota | Replaced by another study | Other (stated, no rule matched) |
| NCT00003926 | Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | Phase 1 | terminated | May 2, 2003 | Masonic Cancer Center, University of Minnesota | Withdrawn due to slow accrual | Enrollment / accrual |
| NCT00944580 | A Vaccine Study for High Risk Cancers | Phase 1 | withdrawn | Jul 23, 2009 | Penn State University | unexpectedly low screening results leading to poor accrual | Enrollment / accrual |
| NCT01339039 | Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma | Phase 1 | terminated | Apr 20, 2011 | Patrick Y. Wen, MD | Low accrual rate | Enrollment / accrual |
| NCT02510950 | Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed… | Phase 1 | terminated | Jul 29, 2015 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT01666600 | NOA-12: BIBF1120 and R-RT in Glioblastoma | Phase 1 / Phase 2 | terminated | Aug 16, 2012 | Prof. Dr. Wolfgang Wick | Interim Analysis for Feasibility | Efficacy / futility |
| NCT02329795 | Image-derived Prediction of Response to Chemo-radiation in Glioblastoma(IDEPREG) | — | terminated | Jan 1, 2015 | Rigshospitalet, Denmark | Slow accrual | Enrollment / accrual |
| NCT00003513 | Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory… | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | slow accrual | Enrollment / accrual |
| NCT01508117 | Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients | Phase 2 | terminated | Jan 11, 2012 | University of Cincinnati | transferred study sponsor | Other (stated, no rule matched) |
| NCT02745756 | A Combined Cell Therapy Approach to the Treatment of Neuroblastoma | Phase 1 | withdrawn | Apr 20, 2016 | H. Lee Moffitt Cancer Center and Research Institute | no enrollment | Enrollment / accrual |
| NCT03013387 | Dosimetry Guided PRRT With 90Y-DOTATOC | Phase 2 | withdrawn | Jan 6, 2017 | Sue O'Dorisio | This project has undergone a significant amount of updates and has been resubmitted under IRB#… | Other (stated, no rule matched) |
| NCT00003469 | Antineoplaston Therapy in Treating Children With Rhabdoid Tumor of the Central Nervous… | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Slow accrual | Enrollment / accrual |
| NCT01526837 | Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma… | Phase 1 | terminated | Feb 6, 2012 | Brain & Spine Surgeons of New York | Investigators decision | Other (stated, no rule matched) |
| NCT01130623 | A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors | Phase 1 | withdrawn | May 26, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01413438 | Bevacizumab With or Without Surgery for Adult Glioblastomas | Phase 2 | withdrawn | Aug 10, 2011 | National Institute of Neurological Disorders and Stroke (NINDS) | not stated | Not stated |
| NCT00112866 | Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive… | Phase 2 | terminated | Jun 3, 2005 | National Cancer Institute (NCI) | due to poor accrual | Enrollment / accrual |
| NCT02439788 | 3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL…(GINAKIT) | Phase 1 | withdrawn | May 12, 2015 | Baylor College of Medicine | Based on newly available preclinical data we changed the CAR construct to a more effective version… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 24, 2018source: clinicaltrials